Related Experiment Video
Updated: Apr 5, 2026
09:29
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
19.2K
Triple-negative Breast Carcinoma: Morphologic and Molecular Subtypes.
1Department of Pathology & Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA.
Advances in Anatomic Pathology
|August 12, 2015
Summary
Triple-negative breast cancer (TNBC) is aggressive and lacks targeted therapies. Understanding TNBC subtypes and molecular advances is crucial for developing new treatments and improving patient outcomes.
Area of Science:
- Oncology
- Pathology
- Molecular Biology
Background:
- Breast carcinoma is a heterogeneous disease.
- Triple-negative breast cancer (TNBC) lacks estrogen, progesterone, and HER2/neu receptors.
- TNBC constitutes 10-20% of breast cancers and exhibits aggressive behavior with poor survival rates.
Purpose of the Study:
- To summarize pathologic subtypes of triple-negative breast cancer.
- To review recent molecular advances in understanding TNBC.
- To highlight the need for targeted therapies and tailored patient management.
Main Methods:
- Review of pathologic subtypes of triple-negative breast cancer.
- Summary of recent molecular advances in the field.
- Analysis of current treatment limitations and future directions.
Main Results:
- TNBC is characterized by aggressive behavior and limited therapeutic options.
- Tumors initially respond to chemotherapy but develop resistance, offering limited long-term benefit.
- Significant heterogeneity at morphologic and molecular levels presents challenges in identifying therapeutic targets.
Conclusions:
- Understanding TNBC heterogeneity is key to developing effective targeted therapies.
- Advances in molecular profiling are essential for personalized treatment strategies.
- Further research is critical for improving outcomes for patients with triple-negative breast cancer.
